FDA adds survival data to Erbitux product labeling

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 10
Volume 16
Issue 10

FDA has approved a supplemental biologics license application for ImClone and Bristol-Myers Squibb's Erbitux (cetuximab) to add monotherapy survival data to the agent's labeling

ROCKVILLE, Maryland—FDA has approved a supplemental biologics license application for ImClone and Bristol-Myers Squibb's Erbitux (cetuximab) to add monotherapy survival data to the agent's labeling. The decision is based on a phase III study showing prolonged overall survival for single-agent Erbitux among 572 patients with EGFR-expressing metastatic colorectal cancer randomized to Erbitux or best supportive care after failure of irinotecan (Camptosar)- and oxaliplatin (Eloxatin)-based regimens.

"Erbitux is now the only approved biologic therapy to demonstrate improved overall survival as a single agent in patients with metastatic colorectal cancer," said Bristol-Myers Squibb's Martin Birkhofer, MD.

Recent Videos
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.